21:34 , May 28, 2019 |  BC Extra  |  Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a patient with gastroesophageal junction adenocarcinoma in a Phase Ib trial to treat locally advanced or...
21:03 , Dec 8, 2017 |  BC Week In Review  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
21:02 , Dec 8, 2017 |  BC Week In Review  |  Company News

Juno licenses gamma secretase inhibitor, related IP

Juno Therapeutics Inc. (NASDAQ:JUNO) announced a trio of licensing agreements to advance its multiple myeloma (MM) program combining gamma secretase inhibitors and tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)-directed chimeric antigen...
23:05 , Dec 6, 2017 |  BC Extra  |  Company News

Juno licenses gamma secretase inhibitor, related IP

Juno Therapeutics Inc. (NASDAQ:JUNO) announced on Wednesday a trio of licensing agreements to advance its multiple myeloma (MM) program combining gamma secretase inhibitors and tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)-directed...
22:07 , Dec 6, 2017 |  BC Extra  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
22:03 , Oct 6, 2017 |  BC Extra  |  Preclinical News

New light on gamma secretase failures in AD

In a study published in Cell Reports this week, researchers from Osaka University added another possible explanation for why gamma secretase /presenilin inhibitors have failed in Alzheimer’s disease trials. The gamma secretase complex acts downstream...